|
gptkbp:instanceOf
|
gptkb:clinical_trial
|
|
gptkbp:clinicalTrialPhase
|
gptkb:NCT00239681
|
|
gptkbp:country
|
multiple countries
|
|
gptkbp:endDate
|
2008
|
|
gptkbp:foundIn
|
rosuvastatin reduced C-reactive protein
rosuvastatin reduced LDL cholesterol
rosuvastatin reduced all-cause mortality
rosuvastatin reduced the incidence of major cardiovascular events
|
|
gptkbp:fullName
|
gptkb:Justification_for_the_Use_of_Statins_in_Prevention:_an_Intervention_Trial_Evaluating_Rosuvastatin
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
JUPITER trial
|
|
gptkbp:participants
|
17802
|
|
gptkbp:population
|
apparently healthy individuals with elevated C-reactive protein
|
|
gptkbp:principalInvestigator
|
gptkb:Paul_Ridker
|
|
gptkbp:publicationYear
|
2008
|
|
gptkbp:publishedIn
|
gptkb:New_England_Journal_of_Medicine
|
|
gptkbp:result
|
prevention of cardiovascular events
|
|
gptkbp:sponsor
|
gptkb:AstraZeneca
|
|
gptkbp:startYear
|
2003
|
|
gptkbp:studiedDrug
|
gptkb:rosuvastatin
|
|
gptkbp:studyType
|
gptkb:clinical_trial
|
|
gptkbp:bfsParent
|
gptkb:Paul_Ridker
|
|
gptkbp:bfsLayer
|
5
|